ANVS
Annovis BioFNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull thesis assumes successful trial readouts and/or favorable regulatory guidance leading to partnership or clear path to late-stage development; market re-rates from micro-cap discount to specialty biotech multiples.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Bear thesis emphasizes binary trial failure, persistent funding needs, and dilution leading to steep share-price declines and potential delisting risk.
Momentum
13
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.90 · Bull $1.80 · Bear $0.45
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-30 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $12.50
Why
Momentum13 · Δ7d -
Value41 · Δ7d +0.1
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
13
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 12.7 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$63.06M
Beta
1.52
Shares Out
26.5M
P/E (TTM) · Derived
-1.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.69
Rev YoY
-
EPS YoY
+62.1%
Gross Margin
-
Op Margin
-
Net Debt
-$10.55M
Current Ratio
4.60
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology